IOL CHEM AND PHARMA
IOLCP · NSE
177.65
-7.28 (-3.94%)
as of 30 Oct 2026 close
Open
186.40
High
186.40
Low
176.02
Prev close
184.93
52w high
224.00
07 Oct 2026
52w low
67.19
16 Mar 2026
VWAP
180.05
Delivery %
34.0%
of volume
Volume 18.09 L · turnover ₹32.57 Cr · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 08 Nov 2010
- Market cap
- ₹5,215 cr
- ISIN
- INE485C01029
- Series
- EQ
- Listed on NSE
- 08 Nov 2010
- Face value
- ₹2
- F&O
- No
Source: NSE equity master · as of 31 Oct 2026 · market cap = shares (30 Sept 2026 filing) × close
Market cap
₹5,215 cr
P/B
2.71
BV ₹66
ROE (TTM)
—
Debt / equity
0.10
P/E (TTM)
—
P/S (TTM)
—
Revenue TTM
—
Net profit TTM
—
Net margin TTM
—
EV / EBITDA
—
Interest cover
—
Revenue growth
—
latest quarter YoY
Profit growth
—
latest quarter YoY
Dividend yield
0.56%
₹1 / share · payout —
Standalone · last four quarters to 2026-09-30 · balance sheet 2026-09-30 · tap a tile for the formula
Daily · NSE EOD
Shareholding · as of 30 Sept 2026
Promoters
62.28%
+0.00 pp QoQ
Public
37.72%
Promoter pledge
0.00%
of promoter shares
FPIs 7.25%
DIIs 0.30%
Mutual funds 0.29%
Insurance —
Retail 25.88%
Government 0.00%
26-06
26-09
Promoter share by quarter · source: NSE shareholding filings (XBRL). DIIs include mutual funds and insurers.
Quarterly results · Consolidated · latest 30 Sept 2026
filed 30 Oct 2026, 10:36 pm IST| ₹ crore | Jun 26* | Sept 26* |
|---|---|---|
| Revenue | 756 | 795 |
| Other income | 8 | 6 |
| Total expenses | 678 | 713 |
| Operating margin | 13.6% | 14.3% |
| Finance costs | 4 | 5 |
| Depreciation | 21 | 22 |
| Profit before tax | 86 | 91 |
| Tax | 22 | 22 |
| Net profit | 64 | 65 |
| Net margin | 8.5% | 8.2% |
| EPS (₹) | 2.20 | 2.21 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison